Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Short Interest Down 5.9% in March

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) saw a significant decrease in short interest in March. As of March 31st, there was short interest totalling 5,280,000 shares, a decrease of 5.9% from the March 15th total of 5,610,000 shares. Based on an average daily volume of 1,200,000 shares, the short-interest ratio is currently 4.4 days.

Alpine Immune Sciences Stock Down 0.1 %

Shares of NASDAQ:ALPN opened at $64.46 on Thursday. Alpine Immune Sciences has a 52 week low of $6.71 and a 52 week high of $64.57. The company has a 50 day moving average price of $38.66 and a two-hundred day moving average price of $24.15.

Alpine Immune Sciences (NASDAQ:ALPN) last issued its earnings results on Monday, March 18th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of ($0.32) by $0.47. Alpine Immune Sciences had a negative net margin of 54.66% and a negative return on equity of 15.54%. The firm had revenue of $30.85 million during the quarter, compared to the consensus estimate of $6.90 million. As a group, equities research analysts anticipate that Alpine Immune Sciences will post -1.74 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ALPN. HC Wainwright lowered shares of Alpine Immune Sciences from a “buy” rating to a “neutral” rating in a research report on Thursday, April 11th. SVB Leerink lowered shares of Alpine Immune Sciences from an “outperform” rating to a “market perform” rating and increased their price objective for the company from $42.00 to $65.00 in a report on Friday, April 12th. Morgan Stanley restated an “equal weight” rating and issued a $65.00 price objective (up from $47.00) on shares of Alpine Immune Sciences in a report on Thursday, April 11th. Leerink Partnrs lowered shares of Alpine Immune Sciences from an “outperform” rating to a “market perform” rating in a report on Thursday, April 11th. Finally, TD Cowen restated a “hold” rating on shares of Alpine Immune Sciences in a report on Tuesday. Eight analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $50.33.

Institutional Investors Weigh In On Alpine Immune Sciences

Several large investors have recently bought and sold shares of ALPN. JPMorgan Chase & Co. increased its stake in Alpine Immune Sciences by 23.4% in the first quarter. JPMorgan Chase & Co. now owns 8,947 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 1,697 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Alpine Immune Sciences by 1.4% during the first quarter. Vanguard Group Inc. now owns 707,598 shares of the biotechnology company’s stock worth $6,347,000 after acquiring an additional 9,844 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Alpine Immune Sciences by 7.6% during the first quarter. Charles Schwab Investment Management Inc. now owns 32,417 shares of the biotechnology company’s stock worth $291,000 after acquiring an additional 2,294 shares in the last quarter. State Street Corp increased its position in shares of Alpine Immune Sciences by 7.1% during the first quarter. State Street Corp now owns 220,621 shares of the biotechnology company’s stock worth $1,979,000 after acquiring an additional 14,609 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Alpine Immune Sciences by 70.8% during the first quarter. Goldman Sachs Group Inc. now owns 22,850 shares of the biotechnology company’s stock worth $205,000 after acquiring an additional 9,471 shares in the last quarter. Institutional investors own 75.17% of the company’s stock.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.